Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05387616
Title A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden (Alternative-C)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ludwig-Maximilians - University of Munich

follicular lymphoma


Copanlisib + Obinutuzumab

Age Groups: adult | senior
Covered Countries DEU

No variant requirements are available.